期刊
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
卷 53, 期 2, 页码 168-173出版社
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyac154
关键词
gastric cancer; preoperative chemotherapy
类别
This study aims to investigate the difference in overall survival between preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy and D2 gastrectomy with postoperative chemotherapy only in patients with clinical T3-4N1-3 M0 locally advanced gastric cancer.
In Japan, postoperative chemotherapy is a standard care for stage II/III gastric cancer after curative resection with D2 lymph node dissection, and the clinical outcomes of patients with stage Ill gastric cancer are unsatisfactory. A combination of oral S-1 and oxaliplatin, that is the standard chemotherapy regimen for unresectable advanced/recurrent gastric cancer associated with a high response rate, was considered the most promising preoperative chemotherapy regimen. This randomized phase Ill trial was started in September 2016 to confirm the superiority of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative chemotherapy compared with D2 gastrectomy with postoperative chemotherapy for patients with clinical T3-4N1-3 M0 locally advanced gastric cancer in terms of overall survival. A total of 470 patients will be enrolled from 63 hospitals in Japan for 8.5 years. This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031180350 [https://jrct.niph.go.jp/latest-detail/jRCTs031180350].
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据